Benzinga's Microcap Movers for Wednesday October 10, 2012
Below are highlights from Benzinga's daily coverage of small cap and microcap securities making big moves:
Shares of Inovio Pharmaceuticals, (NYSE: INO), the Blue Bell, PA developer of vaccines, rose 14.92% Wednesday on 12 times average volume.
Inovio Pharmaceuticals announced Wednesday clinical results indicating that its VGX-3100 therapeutic synthetic vaccine is capable of not only driving robust immune responses to antigens from high risk types of human papillomavirus (HPV) infection but that these immune responses displayed a powerful killing effect on cells changed by HPV into precancerous dysplasias. This desirable effect may ultimately contribute to the regression or elimination of cervical dysplasia and cervical cancer. Inovio is currently assessing the ability of its DNA-based VGX-3100 to treat cervical dysplasias caused by HPV infection in a global phase II trial. Inovio Pharmaceuticals closed at $0.70 on Wednesday.
ZOOM Technologies (NASDAQ: ZOOM), the China-based designer and manufacturer of mobile phones and consumer electronics, rose 12.36% Wednesday on almost 4 average volume.
Zoom Technologies announced Wednesday it has engaged Marcum Bernstein & Pinchuk LLP as its independent auditor for its financial statements audit for the year ended December 31, 2012, and interim review for the three and nine months ended September 30, 2012.
ZOOM Technologies closed at $1.00 on Wednesday.
Shares of ProPhase Labs (NASDAQ: PRPH), the Doylestown, PA manufacturer of over-the-counter cold remedy and consumer products, rose 6.67% Wednesday on 3 times average volume.
Matrixx Initiatives raised its offer on Tuesday to acquire all of the outstanding shares of ProPhase Labs to $1.60 per share.
ProPhase Labs closed at $1.60 on Wednesday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.